Efficacy and Tolerability of Dolutegravir-Based Dual-Therapies in HIV Naive and Switch Patients | Zendy

JM Vinuesa Hernando | Zendy; Galadriel Pellejero-Sagastizabal | Zendy; Mercedes Gimeno-Gracia | Zendy; Isabel SanjoaquinConde | Zendy; María José Crusells-Canales | Zendy; Raquel Fresquet-Molina | Zendy; Raquel Gracia-Piquer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Tolerability of Dolutegravir-Based Dual-Therapies in HIV Naive and Switch Patients

Author(s) -

JM Vinuesa Hernando,

Galadriel Pellejero-Sagastizabal,

Mercedes Gimeno-Gracia,

Isabel SanjoaquinConde,

María José Crusells-Canales,

Raquel Fresquet-Molina,

Raquel Gracia-Piquer

Publication year - 2022

Publication title -

journal of biomedical research and environmental sciences

Language(s) - English

Resource type - Journals

ISSN - 2766-2276

DOI - 10.37871/jbres1395

Subject(s) - tolerability , dolutegravir , medicine , antiretroviral therapy , human immunodeficiency virus (hiv) , oncology , pharmacology , adverse effect , viral load , virology

Objectives: The introduction of dual-therapy both as preferred starting therapy and in switches has been a revolution, allowing the same efficacy results to be obtained as therapies with more Active Ingredients (AI) with a lower risk of toxicity and interactions. The aim of the study is to analyze the efficacy, tolerability and reasons for switching patients to dolutegravir-based dual therapies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research